呼吸机相关性肺炎与COVID-19患者死亡率的关系:coVAPid队列的计划性辅助分析
本研究为多中心回顾性欧洲队列的计划性辅助分析,纳入1576例ICU机械通气患者,其中SARS-CoV-2肺炎568例、流感肺炎482例、无病毒感染证据526例。采用多变量边际Cox回归模型(以撤机、ICU存活出院为感兴趣事件,死亡为竞争事件)分析。结果显示,VAP与SARS-CoV-2组28天死亡率显著升高相关(校正HR 1.70,95%CI 1.16-2.47,p=0.006),流感组亦相关(HR 1.75,95%CI 1.03-3.02,p=0.045),无病毒感染组无显著相关(HR 1.07,95%CI 0.64-1.78,p=0.79)。VAP与SARS-CoV-2组机械通气时间显著延长相关,三组ICU住院时间均显著延长。三组间VAP相关结局的异质性无显著差异。
要点
- 在SARS-CoV-2肺炎机械通气患者中,VAP与28天死亡率显著升高相关:校正HR 1.70(95%CI 1.16-2.47),p=0.006。
- 流感肺炎患者中VAP同样与28天死亡率升高相关:校正HR 1.75(95%CI 1.03-3.02),p=0.045。
- 无病毒感染证据的患者中,VAP与28天死亡率无显著相关:校正HR 1.07(95%CI 0.64-1.78),p=0.79。
- VAP与SARS-CoV-2组机械通气时间显著延长相关,但在流感组和无病毒感染组未观察到显著延长。
- VAP与三组患者ICU住院时间显著延长均相关;三组间VAP相关结局的异质性无显著差异,提示VAP对死亡率的影响在三组间无显著不同。
适用人群与场景
- ICU收治的机械通气患者,包括SARS-CoV-2肺炎、流感肺炎及无病毒感染证据者。
- 多中心回顾性欧洲队列,共纳入1576例患者:SARS-CoV-2肺炎568例、流感肺炎482例、无病毒感染证据526例。
诊断标准与关键阈值
- VAP诊断依据临床、影像学和定量微生物学标准。
研究设计与关键结果
- 研究类型:多中心回顾性欧洲队列的计划性辅助分析,共纳入1576例患者(SARS-CoV-2肺炎568例、流感肺炎482例、无病毒感染证据526例)。
- 主要终点:VAP与28天死亡率的关系。SARS-CoV-2组校正HR 1.70(95%CI 1.16-2.47),p=0.006;流感组校正HR 1.75(95%CI 1.03-3.02),p=0.045;无病毒感染组校正HR 1.07(95%CI 0.64-1.78),p=0.79。
- 次要终点:VAP与SARS-CoV-2组机械通气时间显著延长相关,但在流感组和无病毒感染组未观察到显著延长;VAP与三组ICU住院时间显著延长均相关。
- 三组间VAP相关结局的异质性无显著差异,提示VAP对死亡率的影响在三组间无显著不同。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究的计划性辅助分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在SARS-CoV-2肺炎机械通气患者中,VAP与28天死亡率显著升高相关(校正HR 1.70),提示应重视VAP的预防与早期识别。
- VAP与SARS-CoV-2组机械通气时间及三组ICU住院时间显著延长相关,提示VAP增加医疗资源使用。
- SARS-CoV-2肺炎并未显著改变VAP与28天死亡率的关系(与流感肺炎或无病毒感染相比,异质性无显著差异),提示VAP对预后的影响并非COVID-19特有。
指南或共识出处
- ClinicalTrials.gov注册号NCT04359693。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with SARS-CoV-2 infection are at higher risk for ventilator-associated pneumonia (VAP). No study has evaluated the relationship between VAP and mortality in this population, or compared this relationship between SARS-CoV-2 patients and other populations. The main objective of our study was to determine the relationship between VAP and mortality in SARS-CoV-2 patients.
METHODS: Planned ancillary analysis of a multicenter retrospective European cohort. VAP was diagnosed using clinical, radiological and quantitative microbiological criteria. Univariable and multivariable marginal Cox's regression models, with cause-specific hazard for duration of mechanical ventilation and ICU stay, were used to compare outcomes between study groups. Extubation, and ICU discharge alive were considered as events of interest, and mortality as competing event.
FINDINGS: Of 1576 included patients, 568 were SARS-CoV-2 pneumonia, 482 influenza pneumonia, and 526 no evidence of viral infection at ICU admission. VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 (adjusted HR 1.70 (95% CI 1.16-2.47), p = 0.006), and influenza groups (1.75 (1.03-3.02), p = 0.045), but not in the no viral infection group (1.07 (0.64-1.78), p = 0.79). VAP was associated with significantly longer duration of mechanical ventilation in the SARS-CoV-2 group, but not in the influenza or no viral infection groups. VAP was associated with significantly longer duration of ICU stay in the 3 study groups. No significant difference was found in heterogeneity of outcomes related to VAP between the 3 groups, suggesting that the impact of VAP on mortality was not different between study groups.
INTERPRETATION: VAP was associated with significantly increased 28-day mortality rate in SARS-CoV-2 patients. However, SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, did not significantly modify the relationship between VAP and 28-day mortality.
CLINICAL TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov, number NCT04359693.
参考来源
- Nseir S, Martin-Loeches I, Povoa P, et al. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Crit Care. 2021. PMID: 34034777. doi:10.1186/s13054-021-03588-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。